经皮主动脉瓣置换术治疗退行性 19 毫米主动脉生物瓣。
Transcatheter Aortic Valve Implantation for Degenerated 19-mm Aortic Bioprosthetic Valve.
机构信息
Department of Cardiac Surgery, National Cerebral and Cardiovascular Center.
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center.
出版信息
Circ J. 2017 Dec 25;82(1):289-292. doi: 10.1253/circj.CJ-17-0851. Epub 2017 Nov 11.
BACKGROUND
The valve-in-valve procedure, in which a transcatheter heart valve (THV) is implanted over a prosthetic valve, has been shown to be safe and therapeutically effective, depending on the size of the replacement valve.Methods and Results:We report 3 cases of successful valve-in-valve procedure to replace a degenerated 19-mm stented prosthetic aortic valve. Balloon-expanding THVs were implanted: 20-mm in the 1st case and 23-mm in the next 2. Aortic stenosis was almost completely resolved in all patients, who recovered promptly and without cardiac adverse events.
CONCLUSIONS
Using the valve-in-valve procedure for a 19-mm degenerated bioprosthesis was feasible and safe.
背景
经导管心脏瓣膜（THV）在人工瓣膜上的植入（即 Valve-in-Valve 技术）已被证实是安全且有效的，这取决于置换瓣膜的大小。
方法和结果
我们报告了 3 例成功的 Valve-in-Valve 技术，以替换退行性 19mm 支架人工主动脉瓣。植入了球囊扩张型 THV：第 1 例为 20mm，第 2 例和第 3 例为 23mm。所有患者的主动脉瓣狭窄几乎完全缓解，且患者迅速恢复，无心脏不良事件。
结论
使用 Valve-in-Valve 技术治疗退行性 19mm 生物瓣是可行且安全的。
Zotero 插件